Conviction: Medium
Status: Watching — RSI 36.3 entering oversold zone, price -2.4% in 7D, -2.0% in 30D
Quick Snapshot
| Signal |
Reading |
| Overall |
🟡 RSI 36.3 — approaching oversold. Price $98.61, +1.8% today, -2.4% in 7 days, -2.0% in 30 days. Near 52wk high ($103.18). YTD +22% performance now slightly digesting. |
| Moat |
Moderate-Wide — scale and switching costs, but execution has lagged peers |
| Key insight |
MDT now has fresh OHLC data. RSI 36.3 suggests the post-Q3 enthusiasm is cooling and the stock is approaching an attractive entry zone. Sitting near 52wk high (-4.4%) after +22% YTD run — consolidation is healthy. PFA growth +80%, Hugo FDA cleared, MiniMed spinoff on track. Entry zone is $88-94; current $98.61 is above ideal but RSI approaching watch territory. |
Action Matrix
| Action |
Level |
Why |
| Current |
🔍 Watch |
RSI 36.3 approaching oversold — closer to entry zone. Alert at $92 still active. |
| Entry Zone |
$88 - $94 |
~10-15% pullback from current ~$98; prior support zone |
| Stop-Loss |
$79 (-20%) |
Below 52-week low ($79.55) — thesis-killer territory |
| Target 1 |
$108 (+9%) |
Return to consensus analyst target zone |
| Target 2 |
$117 (+19%) |
All-time high (Sept 2021) — full recovery scenario |
Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| MDT |
$98.61 |
+1.8% |
-2.4% |
-2.0% |
— |
-4.4% |
36 |
🟡 Approaching Oversold |
🔍 Watch |
Legend
- 52wkHi = -4.4% from $103.18 (52-week high in data window)
- 52wk Low = $79.55
- All-Time High = $117.57 (September 8, 2021)
- SMA20 = $100.61 (price is -2.0% below SMA — very close)
- RSI trend: Declining from ~58 (post-Q3) toward 36 — healthy digestion
Price vs Last Deep Dive (02/22)
| Metric |
02/22 |
02/26 |
Change |
| Price |
$97.58 (market data) |
$98.61 (OHLC) |
+$1.03 (+1.1%) |
| RSI |
~58 (estimated) |
36.3 (fresh data) |
-21.7 (significant pullback in RSI) |
| SMA20 |
~$100 (estimated) |
$100.61 |
Now have fresh SMA |
| vs SMA |
~-3% |
-2.0% |
Very close to SMA |
Update from 02/22: MDT now has fresh OHLC data. Price is $98.61, essentially flat from prior estimate ($97.58). RSI has dropped significantly — from an estimated ~58 to 36.3 — reflecting post-Q3 enthusiasm cooling. The stock is -2.0% below SMA20 ($100.61) — nearly at SMA. The -2.4% 7D and -2.0% 30D show digestion of the strong Q3 move. At $98.61 with RSI 36.3, MDT is getting closer to the entry zone but still above the ideal $88-94 level. Watch for continued RSI decline toward 30-35 as the re-entry signal.
Company Overview
One-Liner
Medtronic is the world's largest standalone medical device company by revenue — a $34B/year enterprise spanning heart rhythm management, surgical robotics, spinal implants, neurostimulation, and diabetes technology operating in 150+ countries.
Business Model
| Question |
Answer |
| What they sell |
Implantable and non-implantable medical devices, capital equipment, disposables, software systems |
| Who pays |
Hospitals, health systems, surgical centers, government payers — indirect (devices reimbursed via procedure codes) |
| Revenue model |
Mix of capital equipment (upfront) + high-margin disposables/consumables (recurring), service contracts |
| How sticky |
High — physician training on specific platforms creates lock-in; hospital systems make multi-year purchasing commitments |
Key Segments (Q3 FY2026 — Quarter Ended January 23, 2026)
| Segment |
Q3 Revenue |
Q3 Organic Growth |
FY% |
Key Products |
Notes |
| Cardiovascular |
$3.457B |
+10.6% |
~38% |
PFA/Affera system, TAVR (Evolut), cardiac monitoring, cardiac surgery |
Star segment — PFA +80% global, +137% US |
| Neuroscience |
$2.558B |
+2.5% |
~28% |
Spinal fusion/implants, neuro-stimulation, ENT, surgical navigation |
Slowest growth; spine is structurally sluggish |
| Medical Surgical |
$2.173B |
+2.7% |
~24% |
Hugo surgical robot, endoscopy, respiratory care, renal care |
Hugo FDA cleared Feb 2026 — early innings |
| Diabetes |
$796M |
+8.3% |
~9% |
MiniMed CGM, insulin pumps |
Being spun off as MiniMed (mid-late 2026) |
FY2026 YTD (9 months): Revenue run-rate approaching $34B; 6.0% organic in Q3 is highest in 10 quarters.
Investment Thesis
Bull Case — The Inflection Is Real
| Argument |
Evidence |
Conviction |
| PFA is a genuine multi-year growth driver |
Cardiac Ablation Solutions +80% global, +137% US in Q3 FY26. Affera (Sphere-9) offers dual-energy (PFA + RF) vs. BSX Farapulse (PFA-only). |
🟢 High |
| MiniMed spinoff unlocks value and focus |
Removing GLP-1 narrative overhang; 100+ bps margin uplift post-spinoff. |
🟢 High |
| Hugo FDA clearance opens $13B+ robot market |
Just cleared for urologic procedures Feb 2026. First US procedure at Cleveland Clinic. |
🟡 Medium (early) |
| Dividend aristocrat with 48 years of increases |
$2.84/year annual dividend (~2.9% yield at current price), supported by $3.3B+ in 9-month FCF. |
🟢 High |
| Valuation is modest vs. peer group |
MDT P/E ~26x forward — cheapest large-cap medtech. BSX trades at 57x. SYK at ~35x. |
🟢 Medium-High |
| Tariff headwinds are quantified |
MDT guided $185M tariff impact for FY26 — already priced into guidance. |
🟢 High |
Bear Case — The Value Trap Scenario
| Argument |
Evidence |
Risk Level |
| 10-year history of underperformance |
MDT all-time high was Sept 2021 ($117.57). Still 16% below that. |
🟠 Real |
| Too diversified to move the needle fast |
$34B revenue spread across 4 segments means even 80% PFA growth is diluted. |
🟡 Medium |
| Hugo is years from meaningful revenue |
ISRG has 10,763+ installed systems. Hugo just got first FDA clearance Feb 2026. |
🟠 Real |
| Neuroscience / Spine is a structural drag |
Spine market mature, price-deflationary. MDT's neuro segment grew only 2.5% organically. |
🟡 Medium |
Financial Profile
Revenue Trajectory
| Metric |
FY2023 |
FY2024 |
FY2025 |
FY2026 Guidance |
| Revenue |
~$31.2B |
~$32.4B |
$33.5B |
~$35-36B (est.) |
| Organic Growth |
~4% |
~5% |
~5% |
~5.5% guided |
| Q3 FY26 Organic |
— |
— |
— |
6.0% (best in 10 qtrs) |
Dividend Profile
| Metric |
Value |
| Annual dividend |
$2.84/share |
| Current yield |
~2.9% (at $98.61) |
| Consecutive years of increases |
48 years |
Technical Setup
Current Technicals (Feb 26, 2026)
| Indicator |
Value |
Signal |
| Price |
$98.61 |
Digesting post-Q3 gains |
| RSI (14) |
36.3 |
🟡 Approaching Oversold — declining from ~58 |
| SMA20 |
$100.61 |
Price -2.0% below SMA — very close |
| 52-week range |
$79.55 - $103.18 |
Trading near the top of range |
| YTD performance |
~+22% |
Significant outperformance YTD |
Key Technical Levels
| Level |
Price |
Notes |
| Immediate support |
$93-95 |
Post-Q3 earnings gap-up base |
| Key support |
$88-90 |
Previous resistance turned support; 200-DMA area |
| Strong support |
$79-82 |
52-week low zone |
| Resistance 1 |
$100.61 |
SMA20 — just above |
| Resistance 2 |
$103.18 |
52-week high in data window |
| Long-term target |
$108-117 |
Analyst consensus ($111.77 avg) to ATH recovery |
Catalysts & Timing
| Date |
Event |
Impact |
Watch For |
| Mid-2026 |
MiniMed Diabetes spinoff/IPO |
🟢🟢 |
Removes GLP-1 narrative; potential value unlock |
| Q4 FY26 Earnings (~May 2026) |
Final quarter before FY26 close |
🟢 |
Whether organic growth stays 5.5%+ |
| FY2026-FY2027 |
Hugo US commercial placements |
🟢 |
First disclosed Hugo placement/revenue data |
| Ongoing |
PFA (Affera) market share vs BSX |
🟢 |
Can MDT sustain majority share in new EP labs? |
Entry Strategy
Entry Approach
| Strategy |
Details |
| Current |
Watch — RSI approaching 35, but price still near 52wk high |
| Alert |
$92 — entry zone bottom |
| Entry zone |
$88 - $94 (~10-15% pullback) |
| RSI target for entry |
RSI < 35 with price in $88-94 zone |
| Stop |
$79 (-20% from entry zone) |
Research Log
| Date |
Update |
| 2026-02-22 |
Created deep dive. MDT not in stonks data system. Price ~$97.58 (market data). RSI ~58 (estimated). Q3 FY26 showed strongest enterprise growth in 10 quarters (+6.0% organic). PFA franchise +80%. GLP-1 headwind assessed as overblown. Hugo FDA cleared for urology Feb 2026. Conviction: Medium. Action: Watch, alert at $92. |
| 2026-02-26 |
Fresh OHLC data now available. Price $98.61 (+1.1% vs prior). RSI fresh at 36.3 (was estimated ~58 — now clearly declining). SMA20 $100.61. RSI drop from ~58 to 36.3 shows post-Q3 digestion underway. -2.4% 7D, -2.0% 30D. Getting closer to entry zone ($88-94) but not there yet. Action: Watch, maintain $92 alert. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI dropped from ~58 to 36.3 in 4 days |
Post-Q3 enthusiasm is cooling — approaching entry territory faster than expected |
| SMA20 $100.61, price $98.61 (only -2% gap) |
MDT is right at its moving average — very clean technical level |
| 52wk high $103.18 only 4.4% above current |
Not much room above — upside is toward analyst targets ($108-117) |
| -2.4% 7D while RSI dropped 21+ pts |
Price held relatively well while RSI normalized — constructive |
Open Questions
- What are the specific Hugo US placement numbers from the Q3 FY26 earnings call?
- Is Affera genuinely winning majority share in new EP lab openings?
- What multiple will MiniMed trade at post-spinoff?
- Can MDT sustain 5.5-6% organic growth in FY2027 post-spinoff?
- When does RSI reach the target entry zone (30-35) with price in $88-94?
Mistakes (If Applicable)
| Mistake |
Lesson |
| N/A — first deep dive, no capital deployed |
If entering, wait for pullback to $88-94 — RSI at 36 is better than 58 but entry zone is still below current price |
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.